An improved cocaine hydrolase: The A328Y mutant of human butyrylcholinesterase is 4-fold more efficient

Molecular Pharmacology

Volumn 55, Issue 1, 1999, Pages 83-91

  Xie, Weihua ^a   Altamirano, Cibby Varkey ^a   Bartels, Cynthia F ^d   Speirs, Robert J ^b   Cashman, John R ^b   Lockridge, Oksana ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Hum BioMolecular Research Institute   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYLCHOLINE; CHOLINESTERASE; COCAINE; HYDROLASE;

ARTICLE; BINDING AFFINITY; DETOXIFICATION; ENZYME ACTIVITY; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTOXICATION; PRIORITY JOURNAL;

EID: 0032944436     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.55.1.83     Document Type: Article

References (40)

1. Bartels CF, James K and La Du BN (1992a) DNA mutations associated with the human butyrylcholinesterase J-variant. Am J Hum Genet 50:1104-1114.
2. Bartels CF, Jensen FS, Lockridge O, van der Spek AFL, Rubinstein HM, Lubrano T and La Du BN (1992b) DNA mutations associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphisms. Am J Hum Genet 50:1086-1103.
3. Berkman CE, Underiner GE and Cashman JR (1997) Stereoselective inhibition of human butyrylcholinesterase by phosphonothiolate analogs of (+)-and (-)-cocaine. Biochem Pharmacol 54:1261-1266.
4. Brzezinski MR, Abraham TL, Stone CL, Dean RA and Bosron WF (1994) Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem Pharmacol 48:1747-1755.
5. Das G (1993) Cocaine abuse in North America: a milestone in history. J Clin Pharmacol 33:296-310.
6. Devenyi P (1989) Cocaine complications and pseudocholinesterase. Ann Intern Med 100:167-168.
7. Ellman GL, Courtney KD, Andres V and Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
8. Garry PJ, Dietz AA, Lubrano T, Ford PC, James K and Rubinstein HM (1976) New allele at cholinesterase locus 1. J Med Genet 13:38-42.
9. Gatley SJ (1991) Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem Pharmacol 41:1249-1254.
10. Harel M, Sussman JL, Krejci E, Bon S, Chanal P, Massoulié J and Silman I (1992) Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis. Proc Natl Acad Sci USA 89:10827-10831.
11. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L and Goldfrank LR (1992) Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emerg Med 21:247-253.
12. Hoffman RS, Morasco R and Goldfrank LR (1996) Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. J Toxicol Clin Toxicol 34:259-266.
13. Inaba T, Stewart DJ and Kalow W (1978) Metabolism of cocaine in man. Clin Pharmacol Ther 23:547-552.
14. Izumi M, Maekawa M and Kanno T (1994) Butyrylcholinesterase K-variant in Japan: frequency of allele and associated enzyme activity in serum. Clin Chem 40:1606-1607.
15. Jatlow P, Barash PG, Van Dyke C, Radding J and Byck R (1979) Cocaine and succinylcholine sensitivity: a new caution. Anesth Analg 58:235-238.
16. Kalow W and Grant DM (1995) Pharmacogenetics, in The Metabolic and Molecular Bases of Inherited Disease, 7th edition (Scriver CR, Beaudet AL, Sly WS and Valle D eds) Vol I, pp 307-309, McGraw-Hill, NY.
17. Kalow W and Gunn DR (1957) The relation between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther 120:203-214.
18. Lockridge O (1990) Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther 47:35-60.
19. Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO and Dretchen KL (1997) Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol 145:363-371.
20. Main AR, Soucie WG, Buxton IL and Arinc E (1974) The purification of cholinesterase from horse serum Biochem J 143:733-744.
21. Marzuk PM, Tardiff K, Leon AC, Hirsch CS, Stajic M, Portera L, Hartwell N and Iqbal MI (1995) Fatal injuries after cocaine use as a leading cause of death among young adults in New York city. N Engl J Med 332:1753-1757.
22. Masson P, Legrand P, Bartels CF, Froment MT, Schopfer LM and Lockridge O (1997) Role of aspartate 70 and tryptophan 82 in binding of succinyldithiocholine to human butyrylcholinesterase. Biochemistry 36:2266-2277.
23. Mattes C, Bradley R, Slaughter E and Browne S (1996) Cocaine and butyrylcholinesterase (BChE): Determination of enzymatic parameters. Life Sci 58:257-261.
24. Mattes CE, Lynch TJ, Singh A, Bradley RM, Kellaris PA, Brady RO and Dretchen KL (1997) Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl Pharmacol 145:372-380.
25. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, van der Spek AFL, Lockridge O and LaDu BN (1989) Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci USA 86:953-957.
26. Om A, Ellahham S, Ornato JP, Picone C, Theogaraj J, Corretjer GP and Vetrovec GW (1993) Medical complications of cocaine: Possible relationship to low plasma cholinesterase enzyme. Am Heart J 125:1114-1117.
27. Primo-Parmo SL, Bartels CF, Wiersema B, Van der Spek AFL, Innis JW and La Du BN (1996) Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Am J Hum Genet 58:52-64.
28. Radic Z, Pickering NA, Vellom DC, Camp S and Taylor P (1993) Three distinct domains in the cholinesterase molecule confer selectivity for acetyl-and butyrylcholinesterase inhibitors. Biochemistry 32:12074-12084.
29. Ralston JS, Main AR, Kilpatrick BF and Chasson AL (1983) Use of procainamide gels in the purification of human and horse serum cholinesterases. Biochem J 211: 243-250.
30. Rich JA and Singer DE (1991) Cocaine-related symptoms in patients presenting to an urban emergency department. Ann Emerg Med 20:616-621.
31. Rowbotham MC (1992) Cocaine levels and elimination in inpatients and outpatients: implications for emergency treatment of cocaine complications. NIDA Res Monogr 123:147-155.
32. 1k, another quantitative variant at cholinesterase locus 1. J Med Genet 15:27-29.
33. Schrank KS (1992) Cocaine-related emergency department presentations. NIDA Res Monogr 123:110-128.
34. Schwartz HJ and Johnson D (1996) In vitro competitive inhibition of plasma cholinesterase by cocaine: normal and variant genotypes. J Toxicol Clin Toxicol 34:77-81.
35. Stewart DJ, Inaba T, Tang BK and Kalow W (1977) Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci 20:1557-1564.
36. Stewart DJ, Inaba T, Lucassen M and Kalow W (1979) Cocaine metabolism: Cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther 25:464-468.
37. Van Dyke C, Barash PG, Jatlow P and Byck R (1976) Cocaine: Plasma concentrations after intranasal application in man. Science 191:859-861.
38. Warner EA (1993) Cocaine abuse. Ann Intern Med 119:226-235.
39. Wetli CV (1987) Fatal reactions to cocaine, in Cocaine, a Clinicīan's Handbook (Washton AM and Gold MS, eds) pp 33-54, Guilford Press, NY.
40. Whittaker M (1986) Cholinesterase. Monographs in Human Genetics. vol 11, S. Karger AG, Basel, Switzerland.